RHINOCORT ALLERGY SPRAY OTC
Generic Name and Formulations:
Budesonide 32mcg; per nasal spray; scent- and alcohol-free.
McNeil Consumer Healthcare
Indications for RHINOCORT ALLERGY SPRAY:
To relieve symptoms of seasonal or perennial allergic rhinitis.
Adults and Children:
<6yrs: not recommended. 6–<12yrs: initially 1 spray in each nostril once daily; increase to 2 sprays per nostril once daily if no improvement; reduce to 1 spray in each nostril once daily when symptoms improve. ≥12yrs: use 2 sprays per nostril once daily; reduce to 1 spray in each nostril once daily when symptoms improve.
Do not use for treating the common cold or use more than recommended. Avoid eyes or mouth. Recent nose ulcers or surgery. Nose injury that has not healed. Eye infection. Glaucoma. Cataracts. Re-evaluate if no improvement after 2 weeks. Discontinue if exposed to chickenpox, measles, or tuberculosis, have symptoms of an infection (eg, persistent fever), change in vision, severe or frequent nosebleeds. Children 6–<12yrs: monitor and re-evaluate if treatment requires >2 months per year. Pregnancy. Nursing mothers.
Concomitant other steroid drugs for asthma, allergies, or skin rash.
Reduced growth velocity in children.
Spray—5mL (60 sprays), 8.4mL (120 sprays)
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored